|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Center MM, Jemal A, Smith RA and Ward E:
Worldwide variations in colorectal cancer. CA Cancer J Clin.
59:366–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Edwards BK, Ward E, Kohler BA, Eheman C,
Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I,
Seeff LC, et al: Annual report to the nation on the status of
cancer, 1975–2006, featuring colorectal cancer trends and impact of
interventions (risk factors, screening, and treatment) to reduce
future rates. Cancer. 116:544–573. 2010. View Article : Google Scholar
|
|
4
|
Fang YJ, Wu XJ, Zhao Q, Li LR, Lu ZH, Ding
PR, Zhang RX, Kong LH, Wang FL, Lin JZ, et al: Hospital-based
colorectal cancer survival trend of different tumor locations from
1960s to 2000s. PLoS One. 8:e735282013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carmen Figueroa-Aldariz M,
Castañeda-Patlán MC, Santoyo-Ramos P, Zentella A and Robles-Flores
M: Protein phosphatase 2A is essential to maintain active Wnt
signaling and its Abeta tumor suppressor subunit is not expressed
in colon cancer cells. Mol Carcinog. 54:1430–1441. 2015. View Article : Google Scholar
|
|
6
|
Perrotti D and Neviani P: Protein
phosphatase 2A: A target for anticancer therapy. Lancet Oncol.
14:e229–e238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ohama T: Targeting PP2A inhibitors as a
novel anti-cancer strategy] Nihon Yakurigaku Zasshi. 145:293–298.
2015.In Japanese.
|
|
8
|
Coles A: Newer therapies for multiple
sclerosis. Ann Indian Acad Neurol. 18(Suppl 1): S30–S34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao M, Liu Y, Xiao Y, Han G, Jia L, Wang
L, Lei T and Huang Y: Prolonging survival of corneal
transplantation by selective sphingosine-1-phosphate receptor 1
agonist. PLoS One. 9:e1056932014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jin J, Zhang HJ, Wang XJ, Zhou WQ, Yin DL
and Chen XG: Effect of a novel selective S1P1 agonist, Syl948, on
mouse skin transplantation. Yao Xue Xue Bao. 49:627–631. 2014.In
Chinese. PubMed/NCBI
|
|
11
|
Brinkmann V: FTY720: Mechanism of action
and potential benefit in organ transplantation. Yonsei Med J.
45:991–997. 2004. View Article : Google Scholar
|
|
12
|
Kovarik JM, Schmouder R, Barilla D,
Riviere GJ, Wang Y and Hunt T: Multiple-dose FTY720: Tolerability,
pharmacokinetics, and lymphocyte responses in healthy subjects. J
Clin Pharmacol. 44:532–537. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rybaczek D, Musiałek MW and Balcerczyk A:
Caffeine-induced premature chromosome condensation results in the
apoptosis-like programmed cell death in root meristems of Vicia
faba. PLoS One. 10:e01423072015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Van Hoof C and Goris J: Phosphatases in
apoptosis: To be or not to be, PP2A is in the heart of the
question. Biochim Biophys Acta. 1640:97–104. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu Z, Wang J, Zheng T, Liang Y, Yin D,
Song R, Pei T, Pan S, Jiang H and Liu L: FTY720 inhibits
proliferation and epithelial-mesenchymal transition in
cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer.
14:7832014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao Y, Guo Q, Chen J, Hu J, Wang S and
Sun Y: Role of long non-coding RNA HULC in cell proliferation,
apoptosis and tumor metastasis of gastric cancer: A clinical and in
vitro investigation. Oncol Rep. 31:358–364. 2014.
|
|
17
|
Alinari L, Baiocchi RA and Praetorius-Ibba
M: FTY720-induced blockage of autophagy enhances anticancer
efficacy of milatuzumab in mantle cell lymphoma: Is FTY720 the next
autophagy-blocking agent in lymphoma treatment? Autophagy.
8:416–417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang N, Qi Y, Wadham C, Wang L, Warren A,
Di W and Xia P: FTY720 induces necrotic cell death and autophagy in
ovarian cancer cells: A protective role of autophagy. Autophagy.
6:1157–1167. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mizushima N, Yoshimori T and Levine B:
Methods in mammalian autophagy research. Cell. 140:313–326. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kabeya Y, Mizushima N, Ueno T, Yamamoto A,
Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T: LC3, a
mammalian homologue of yeast Apg8p, is localized in autophagosome
membranes after processing. EMBO J. 19:5720–5728. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kabeya Y, Mizushima N, Yamamoto A,
Oshitani-Okamoto S, Ohsumi Y and Yoshimori T: LC3, GABARAP and
GATE16 localize to autophagosomal membrane depending on form-II
formation. J Cell Sci. 117:2805–2812. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cristóbal I, Manso R, Rincón R, Caramés C,
Senin C, Borrero A, Martínez-useros J, Rodriguez M, Zazo S,
Aguilera O, et al: PP2A inhibition is a common event in colorectal
cancer and its restoration using FTY720 shows promising therapeutic
potential. Mol Cancer Ther. 13:938–947. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu HC, Hou DR, Liu CY, Lin CS, Shiau CW,
Cheng AL and Chen KF: Cancerous inhibitor of protein phosphatase 2A
mediates bortezomib-induced autophagy in hepatocellular carcinoma
independent of proteasome. PLoS One. 8:e557052013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ahmed D, de Verdier PJ, Ryk C, Lunqe O,
Stål P and Flygare J: FTY720 (Fingolimod) sensitizes hepatocellular
carcinoma cells to sorafenib-mediated cytotoxicity. Pharmacol Res
Perspect. 3:e001712015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Estella-Hermoso de Mendoza A,
Castello-Cros R, Imbuluzqueta E, Cirauqui C, Pippa R, Odero MD and
Blanco-Prieto MJ: Lipid nanosystems enhance the bioavailability and
the therapeutic efficacy of FTY720 in acute myeloid leukemia. J
Biomed Nanotechnol. 11:691–701. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hait NC, Avni D, Yamada A, Nagahashi M,
Aoyagi T, Aoki H, Dumur CI, Zelenko Z, Gallagher EJ, Leroith D, et
al: The phosphorylated prodrug FTY720 is a histone deacetylase
inhibitor that reactivates ERα expression and enhances hormonal
therapy for breast cancer. Oncogenesis. 4:e1562015. View Article : Google Scholar
|
|
27
|
Cristóbal I, González-Alonso P, Daoud L,
Solano E, Torrejón B, Manso R, Madoz-gúrpide J, Rojo F and
García-Foncillas J: Activation of the tumor suppressor PP2A emerges
as a potential therapeutic strategy for treating prostate cancer.
Mar Drugs. 13:3276–3286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu Q, Zhao X, Frissora F, Ma Y, Santhanam
R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, et al:
FTY720 demonstrates promising preclinical activity for chronic
lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood.
111:275–284. 2008. View Article : Google Scholar
|
|
29
|
Mizushima N and Yoshimori T: How to
interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Klionsky DJ, Abdalla FC, Abeliovich H,
Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M,
Agostinis P, Aguirre-Ghiso JA, et al: Guidelines for the use and
interpretation of assays for monitoring autophagy. Autophagy.
8:445–544. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barth S, Glick D and Macleod KF:
Autophagy: Assays and artifacts. J Pathol. 221:117–124. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kroemer G, Galluzzi L, Vandenabeele P,
Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS,
Golstein P, Green DR, et al Nomenclature Committee on Cell Death
2009: Classification of cell death: Recommendations of the
Nomenclature Committee on Cell Death 2009. Cell Death Differ.
16:3–11. 2009. View Article : Google Scholar :
|
|
33
|
Gómez VE, Giovannetti E and Peters GJ:
Unraveling the complexity of autophagy: Potential therapeutic
applications in Pancreatic Ductal Adenocarcinoma. Semin Cancer
Biol. 35:11–19. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ozpolat B and Benbrook DM: Targeting
autophagy in cancer management - strategies and developments.
Cancer Manag Res. 7:291–299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maiuri MC, Zalckvar E, Kimchi A and
Kroemer G: Self-eating and self-killing: Crosstalk between
autophagy and apoptosis. Nat Rev Mol Cell Biol. 8:741–752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Seglen PO and Gordon PB: 3-Methyladenine:
Specific inhibitor of autophagic/lysosomal protein degradation in
isolated rat hepatocytes. Proc Natl Acad Sci USA. 79:1889–1892.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Böckelman C, Koskensalo S, Hagström J,
Lundin M, Ristimäki A and Haglund C: CIP2A overexpression is
associated with c-Myc expression in colorectal cancer. Cancer Biol
Ther. 13:289–295. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Teng HW, Yang SH, Lin JK, Chen WS, Lin TC,
Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, et al: CIP2A is a
predictor of poor prognosis in colon cancer. Journal of
gastrointestinal surgery. 16:1037–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ding Y, Wang Y, Ju S, Wu X, Zhu W, Shi F
and Mao L: Role of CIP2A in the antitumor effect of bortezomib in
colon cancer. Mol Med Rep. 10:387–392. 2014.PubMed/NCBI
|
|
40
|
Zhang N, Wu ZM, Mcgowan E, Shi J, Hong ZB,
Ding CW, Xia P and Di W: Arsenic trioxide and cisplatin synergism
increase cytotoxicity in human ovarian cancer cells: therapeutic
potential for ovarian cancer. Cancer Sci. 100:2459–2464. 2009.
View Article : Google Scholar : PubMed/NCBI
|
